Twist Bioscience Corporation last reported quarterly results on Aug 3, 2026, for Q3 FY2026 (the quarter ended Jun 30, 2026): revenue of $118.4 million (+23.2% year over year) and diluted EPS of -$0.56. It usually reports 12–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q4 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
118
+23.2%
|
-35
-271.9%
|
-0.56
-269.7%
|
|
May 4, 2026
34 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
111
+19.3%
|
-44
-11.9%
|
-0.71
-7.6%
|
|
Jan 12, 2026
12 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
104
+16.9%
|
-31
+3.4%
|
-0.50
+5.7%
|
|
Nov 14, 2025
45 days after quarter end
|
Q4 FY2025
ended Sep 30, 2025
|
99
+16.9%
|
-27
+21.7%
|
-0.45
+24.0%
|
|
Aug 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
96
+17.9%
|
20
+123.8%
|
0.33
+122.4%
|
|
May 5, 2025
35 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
93
+23.2%
|
-39
+13.5%
|
-0.66
+16.5%
|
|
Feb 3, 2025
34 days after quarter end
|
Q1 FY2025
ended Dec 31, 2024
|
89
+24.1%
|
-32
+26.5%
|
-0.53
+29.3%
|
|
Nov 18, 2024
49 days after quarter end
|
Q4 FY2024
ended Sep 30, 2024
|
85
+26.5%
|
-35
+25.1%
|
-0.59
+26.8%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TWST (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1581280
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.